• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Revive Therapeutics Ltd (OP: RVVTF )

    0.0080 -0.0026 (-24.53%)
    Streaming Delayed Price Updated: 10:24 AM EDT, Aug 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 52,305
    Open 0.0076
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0106
    Today's Range 0.0068 - 0.0086
    52wk Range 0.0060 - 0.0431
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
    Via Benzinga
    Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -64.44%
    -64.44%
    1 Month
    -25.93%
    -25.93%
    3 Month
    -59.80%
    -59.80%
    6 Month
    -61.90%
    -61.90%
    1 Year
    -55.56%
    -55.56%

    More News

    Read More
    Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Corporate Update
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Explores the Use of Bucillamine for Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.